Modelling vaccination schedules for a cancer immunoprevention vaccine

We present a systematic approach to search for an effective vaccination schedule using mathematical computerized models. Our study is based on our previous model that simulates the cancer vs immune system competition activated by tumor vaccine. This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma. In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma. The full protection was conferred using chronic (prophylactic) vaccination protocol while therapeutic vaccination was less effcient.In the present paper we use the computer simulations to systematically search for a vaccination schedule which prevents solid tumor formation. The strategy we used for defining a successful vaccination schedule is to control the number of cancer cells with vaccination cycles. We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

[1]  P. Delves,et al.  The Immune System , 2000 .

[2]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[3]  C. Hamers-Casterman,et al.  A new allotype in the rabbit linked with As1 which may characterize a new class of IgG , 1966 .

[4]  Piero Musiani,et al.  Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine , 2004, Cancer Research.

[5]  Évin,et al.  A CONTROLLED TRIAL OF A HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE , 2022 .

[6]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[7]  P. Delves,et al.  Advances in immunology: The immune system - Second of two parts. , 2000 .

[8]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[9]  M. Pulvirenti,et al.  Modelling in Applied Sciences: A Kinetic Theory Approach , 2004 .

[10]  L. A. Segel,et al.  Some Reflections on Memory in Shape Space , 1989 .

[11]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[12]  L D Greller,et al.  Tumor heterogeneity and progression: conceptual foundations for modeling. , 1996, Invasion & metastasis.

[13]  M. Eaman Immune system. , 2000, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[14]  Vladimir Brusic,et al.  Mathematical Modelling of the Immune System , 2004 .

[15]  P. Musiani,et al.  Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[16]  Luigi Preziosi,et al.  Modelling Mathematical Methods and Scientific Computation , 1995 .

[17]  Luigi Preziosi,et al.  Multiscale modeling and mathematical problems related to tumor evolution and medical therapy. , 2003 .

[18]  Filippo Castiglione,et al.  Modeling and simulation of cancer immunoprevention vaccine , 2005, Bioinform..

[19]  P. Musiani,et al.  Immunoprevention of cancer: is the time ripe? , 2000, Cancer research.

[20]  G. Trinchieri,et al.  Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.